Site: Netherlands
	Covid Positive	Covid negative		Percent with feature	Percent COVID positive	Hazard s ratio	95% CI	P	Comments
Sarcoidosis (996 who live in the Netherlands , out of 1034 respondents )	23	973	996		2.31%
Male	6	418	424	21.60%	1.42%	0.4745	0.1187-1.1932	>0.10
Female	17	553	570	29.04%	2.98%				2 no sex indicated
White	22	932	954	48.60%	2.31%	0.9682	0.1337-7.0165	>0.10
Other	1	41	42	2.14%	2.38%
BMI categories
BMI < 25	8	348	356	18.14%	2.25%	0.958	0.4029-2.2323	>0.10
BMI ≥ 25	15	623	638	32.50%	2.35%
Current meds
Prednisone	4	194	198	10.09%	2.02%	0.84585	0.2919-2.4661	>0.01	of 28 patients the dose is missing
No prednisone	19	779	987	40.65%	2.38%
Prednisone ≥ 10 mg	2	76	78	3.97%	2.56%	1.1795	0.1701-8.1803	>0.10
Prednisone < 10mg	2	90	92	4.69%	2.17%
Plaquenil	1	57	58	2.95%	1.72%	0.7351	0.1008-5.3585	>0.10
No plaquenil	22	916	938	47.78%	2.35%
anti-TNF (infliximab (6), adalimumab (7))	0	76	76	3.87%	0.00%	0.2545	0.01561-4.14497	>0.10
no anti-TNF (de lege cellen uit dezelfde kolommen)	23	897	920	46.87%	2.50%				1 patient was treated with both infliximab and adalimumab
Cytotoxic (methotrexa te (2), azathioprine (3), leflunomide (5))	2	227	229	11.67%	0.87%	0.319	0.07536-1.3502	>0.10
No cytotoxic (lege cellen in dezelfde kolommen)	21	746	767	39.07%	2.74%				3 patients were treated with both methotrexat e and azathioprine
Rituximab
yes	0	1	1	0.05%	0.00%	10.5957	0.9295-120.7801	0.0573
no	23	972	995	50.69%	2.31%
Current medication
yes	7	515	572	26.74%	1.34%	0.40	0.165-0.958	<0.05
no	16	458	474	24.04%	3.38%
Underlying
COPD	0	20	20	1.02%	0.00%	0.9899	0.6217-15.7596	>0.10
	23	953	976	49.72%	2.36%
Asthma	2	80	82	4.18%	2.44%	1.0616	0.2534-4.448	>0.10
	21	893	914	46.56%	2.30%
Diabetes	2	47	49	2.50%	4.08%	1.8406	0.441-7.628	>0.10	(past) use of prednison can be studied additionally
	21	926	947	48.24%	2.22%
Heart failure	0	27	27	1.38%	0.00%	0.7371	0.04592-11.8322	>0.10
	23	946	969	49.36%	2.37%
Circulation	2	35	37	1.88%	5.41%	2.4685	0.601-10.1387	>0.10
	21	938	959	48.85%	2.19%
Hypertension	1	107	108	5.50%	0.93%	0.3737	0.05088-2.7452	>0.10
	22	866	888	45.24%	2.48%
Cancer	0	20	20	1.02%	0.00%	0.9899	0.06217-15.7596	>0.10
	23	953	976	49.72%	2.36%
Organ involved
Lung	20	820	840	42.79%	2.38%	1.2381	0.3724-4.1165	>0.10
no Lung	3	153	156	7.95%	1.92%
heart	0	115	115	5.86%	0.00%	0.1618	0.009892-2.645	>0.10
no heart	23	858	881	44.88%	2.61%
CNS	1	118	119	6.06%	0.84%	0.335	0.04557-2.426	>0.10
no CNS	22	855	877	44.68%	2.51%
Sarcoid age
COVID positive							55.3 ± 6.0 years
COVID negative							55.0±10. 8 years
COVID uncertain							50.5 ± 11.0 years
COVID outcome	Home	Hospital	ICU	Vent
Sarc	20	3	0	0.00%
Sarc ≥ 5 yr	15	678	693	70.14%	2.16%	0.912	0.3758-2.2141	>0.10
Sarc < 5 yr	7	288	295	29.86%	2.37%				8 unknown
			988
Roommates with COVID-19
yes	11	30	41	4.12%	26.83%	21.3516	10.0247-45-4768	<0.0001
no	12	943	955	95.88%	1.26%
			996
Work in healthcare
Yes	4	99	103	10.34%	3.88%	1.8252	0.6331-5.2618	>0.10
No	19	874	893	89.66%	2.13%
			996
COVID positive	Home	Hospital		Perce nt on drug	Percent treate d in hospit al				If in hospital, considered
									bad outcome
									Hazard ration for
Prednisone									Hospitalization
Yes	4	0	4	17.39%	0.00%	0.5714	0.03487-9.3644	>0.10
No	16	3	19	82.61%	15.79%
Prednisone ≥ 10 mg	2	0	2	50.00%	0.00%				TOO SMALL
Prednisone < 10mg	2	0	2	50.00%	0.00%
Infliximab									there were no COVID - 19 positive patients who were treated with infliximab
Plaquenil
Yes	1	0	1	4.35%	0.00%	1.6428	0.1236-21.835	>0.10
No	19	3	22	95.65%	13.64%
Cytotoxic
yes	2	0	2	8.70%	0.00%	1.0476	0.06994-15.6914	>0.10
no	18	3	21	91.30%	14.29%
Rituximab
									none of the COVID-19 positive patients was treated with rituximab